Centre for Skin Diseases

Deals with various skin conditions

Dermatology is the branch of medicine that focuses on conditions that affect our body’s largest organ, i.e. skin. The term comes from the Greek word derma, which means skin or hide. In addition to the skin, dermatology also includes conditions that affect our nails, hair, and the delicate lining of the eyelids, nose, and mouth. There are about 1500 distinct skin diseases and few more variants that could be found in an average 15% population with skin problems. Moreover, it is said that 50 to 75% of individuals are prone to developing skin problems at any time in their lives. Therefor, caring for it is important to the overall health.

exRNA Therapeutics Limited has been able to discover a potential drug therapy that contains RNA, and by using this drug the pathways associated with the autoimmune skin diseases could be down regulated. We hypothesize that quantification of target gene miRNA expression in genes might be useful and hopefully be a non-invasive approach to monitor the disease activity as well as treatment response of all autoimmune skin diseases.

We are trying to down regulate pathways associated with interleukins, interferon, and cytokines based on our studies. The targets we have studied includes- IL17, 17A, IL-1,2,4,5,6,12,22,23,33, TLR-6,7,8,9, CD20,40, 151, IFNα, IFNϒ, TNFα, NFkβ, MMP-9,13, CDK-N1α, CDK-1β, and CDKN2A.

These specific pathways could serve as drug targets for chronic and acute skin fibrosis conditions.

Significant diseases- Psoriasis, Lupus of the skin, Morphea/Scleroderma, Eczemas burn, Bechet’s disease, Lichen planus, Dermatomyositis, Pemphigoid.

Systematic therapies- Immunomodulators, and a few novel injectable products.

Psoriasis is a chronic autoimmune disease that causes red, itchy, and scaly patches on the skin. Such patches can be formed anywhere on the body but typically occur on the inside of the elbows, knees, and scalp.

Psoriasis is caused by a complex interplay between the immune system, psoriatic-associated susceptibility loci, autoantigens, and multiple environmental factors. Psoriasis represents a T cell-mediated disease primarily driven by pathogenic T cells that produce high levels of IL-17 in response to IL-23.

The activation and upregulation of IL-17 in pre-psoriatic skin produce a “feed-forward” inflammatory response in keratinocytes. It is self-amplifying and drives the development of mature psoriatic plaques by inducing epidermal hyperplasia, epidermal cell proliferation, and recruitment of leukocyte subsets into the skin.

Psoriasis can be triggered by various factors in genetically susceptible individuals, including trauma, infection (such as streptococcal infection), and medications.

Many abnormalities have been observed involving antigen presentation, activation of NF-Kb signaling pathways, differentiation of T helper cell populations, and enhanced IL-17 response and infiltration of immune cells.

IL-22 and IL-23 stimulate bone formation while Tumor Necrosis Factor (TNF) enhances bone resorption and the IL-17A stimulates both processes.

Go To Previous